Respiratory Syncytial Virus Pneumonia Treated with Lower-Dose Palivizumab in a Heart Transplant Recipient

Table 1

Pulmonary function tests two months prior to admission and at three months followup.

PFT	Prior to admission	Followup
FVC (liters), (% predicted)	2.01, (45%)	2.76, (68%)
FEV1 (liters), (% predicted)	1.58, (53%)	2.21, (74%)
FEV1/FVC (% predicted)	78	80

FVC: forced vital capacity, FEV1: forced expiratory volume in one second.